KSKlaudia Sobczak

Klaudia Sobczak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Klaudia Sobczak has a total of 67 co-authors. Here are the top co-authors by number of shared publications:

  • Jesús Jiménez-Barbero

    Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain

    3 shared publications
  • June Ereño-Orbea

    Cancer Glycoimmunology Laboratory Center for Cooperative Research in Biosciences (CIC bioGUNE) Basque Research and Technology Alliance (BRTA) Derio Spain

    3 shared publications
  • Antonio Franconetti

    Chemical Glycobiology Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain

    2 shared publications
  • Felix Elortza

    Proteomics Platform, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), CIBERehd, Bizkaia Science and Technology Park, 48160 Derio, Spain

    2 shared publications
  • Iker Oyenarte

    Cancer Glycoimmunology Laboratory Center for Cooperative Research in Biosciences (CIC bioGUNE) Basque Research and Technology Alliance (BRTA) Derio Spain

    2 shared publications
  • Maria Jesús Moure

    Chemical Glycobiology Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), 48160 Derio, Bizkaia, Spain

    2 shared publications

Latest Publications

  • Open Access

    Molecular basis of Siglec-10 ligand recognition and antibody blockade

    by Klaudia Sobczak, Asier Antoñana-Vildosola, Pablo Valverde, Eunate Valdaliso-Díez, Amaia Mentxaka, Maria Alejandra Travecedo, Zeinab Jame-Chernaboo, Edward N. Schmidt, Larissa Heinze, Silvia D’ANdrea, et al.

    Siglec-10 is a sialic acid-binding immunoglobulin-like lectin implicated in immune regulation, yet the molecular basis for ligand recognition and how this is functionally linked to immune modulation remains poorly defined. Herein, we present a multidisciplinary study encompassing structural, biochemical, and cellular approaches to elucidate Siglec-10-carbohydrate interactions and their functional consequences. The crystal structure of the extracellular domain of Siglec-10 in complex with α2-6 sialyllactose revealed the presence of two key arginine residues within the Siglec-10 binding site that interact with the carboxyl group of sialic acid, the canonical R119 and R127, suggesting potential dual contributions to ligand engagement. Saturation Transfer Difference (STD)-Nuclear Magnetic Resonance (NMR) confirmed that R119 is essential for sialoglycan binding in solution, whereas R127 appears dispensable for interactions with glycans under these conditions. In contrast, cell-based binding assays using primary human T cells and engineered monocytic lines demonstrated that both arginine residues (R119 and R127) are critical for cellular recognition, revealing a context-dependent interaction. By obtaining direct images at a molecular resolution of 6-7 nm, super-resolution microscopy further revealed glycan-independent dimerization of the Siglec-10 receptor on the surface of human monocytes. Ligand blockade mediated by anti-Siglec-10 mAb (clone S10A) restores CAR-T cell cytotoxicity in vitro , supporting its role as an immune checkpoint receptor. Finally, although CD24 was not identified as a Siglec-10 ligand on T cells, proximity labeling and mass spectrometry uncovered other sialylated glycoproteins that may mediate this interaction. Together, these results identify Siglec-10 as a modulatory receptor with structural and functional features distinct from other Siglec family members and highlight its potential for therapeutic targeting in cancer immunotherapy.


  • Open Access

    Loss of UFMylation supports prostate cancer metastasis and rewires cell metabolism towards hexosamine biosynthesis

    by Laura Bozal-Basterra, María-Camila Salazar, Ana Margarida Ferreira Campos, Margherita Demicco, Daniel R. Schmidt, Klaudia Sobczak, June Ereño-Orbea, Patricia Altea-Manzano, Ainara Miranda Villanueva, Belén Martínez La Osa, et al.

    The acquisition of metastatic features in tumor cells encompasses genetic and non-genetic adaptation, including reprogramming of cellular metabolism. Here we show that loss of UFMylation reroutes glucose metabolism, promotes invasive capacity and supports prostate cancer metastasis. Through transcriptome-based bioinformatics analysis, we identified a reduction in the ubiquitin-like modifier UFM1 and its ligase UFL1 in metastatic prostate cancer. We demonstrate that loss of UFMylation results in enhanced cancer cell dissemination and a switch from cellular proliferation to invasion. Using biotin-based proteomics, we identified phosphofructokinase (PFKAP) as an unprecedented UFMylation substrate. Consistent with UFMylation playing a role in the regulation of phosphofructokinase activity, loss of UFMylation reduced glucose metabolism in favour of hexosamine biosynthesis, which resulted in elevated glycosylation of proteins relevant for cell invasion. These results reveal a role for UFMylation in the regulation of phosphofructokinase and glucose metabolism to support prostate cancer metastasis.

  • Open Access

    Exploring Glycan‐Lectin Interactions in Natural‐Like Environments: A View Using NMR Experiments Inside Cell and on Cell Surface

    by Sara Bertuzzi, Marta G. Lete, Antonio Franconetti, Tammo Diercks, Sandra Delgado, Iker Oyenarte, Maria J. Moure, Reyes Nuñez‐Franco, Pablo Valverde, Maria Pia Lenza, et al.

    Glycan‐mediated molecular recognition events are essential for life. NMR is widely used to monitor glycan binding to lectins in solution using isolated glycans and lectins. In this context, we herein explore diverse NMR methodologies, from both the receptor and ligand perspectives, to monitor glycan‐lectin interactions under experimental conditions mimicking the native milieu inside cells and on cell surface. For the NMR experiments inside cells, galectin‐7 is employed as model, since most galectins are soluble and carry out their functions in the cellular micro‐environment. Using Danio Rerio oocytes, the 1H‐15N HMQC NMR spectrum of a folded galectin has been observed inside cell for the first time, using a glycomimetic ligand (TDG) to overcoming the natural tendency of galectins to bind to numerous galactose‐containing receptors within cells. Alternatively, most lectins, other than galectins, are displayed on the cell surface, providing a multivalent presentation to bind their glycan partners in cis (at the same cell) or in trans (on other cells). In this case, ligand‐based STD‐NMR experiments have been successfully applied to account for the interactions of natural glycans and glycomimetics with Siglec‐10. These methodologies provide the proof‐of‐concept to open the door to the NMR analysis of the recognition of glycans in native‐like settings.